Navigation Links
Boston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries
Date:2/8/2012

NATICK, Mass., Feb. 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of the TruePath™ CTO Device, designed to facilitate the crossing of chronic total occlusions (CTOs, or complete blockages) within the peripheral vasculature.  The Company will begin marketing the product immediately in the U.S. and expects to launch the product in Europe and other international markets in the first half of 2012.

CTOs, which represent complete artery blockages, are extremely difficult to treat with standard endovascular devices such as guidewires and other catheter-based technologies.  CTO devices permit endovascular treatment in cases that otherwise might require a patient to undergo bypass surgery or risk lower extremity amputation. 

"CTOs are very challenging, requiring additional time, resources and patient exposure to imaging contrast and radiation," said J. A. Mustapha, M.D., Director of Endovascular Intervention at Metro Health Hospital in Wyoming, MI.  "The TruePath device is an exciting new technology that allows me to effectively penetrate these difficult blockages with greater speed and ease, allowing access to untreated lesions and helping to improve overall patient outcomes."

The TruePath CTO Device features a rotating diamond-coated tip designed to break through occluded peripheral arteries and facilitate the placement of conventional guidewires for treatment of peripheral lesions.  The ultra-low 0.018" profile is roughly half the size of competitive devices and is engineered for optimal crossing.  Once positioned, the distal tip rotates at 13,000 rpm to facilitate drilling through calcified lesions and other fibrous blockages.  The TruePath device requires no capital equipment and is available with an optional extension wire to facilitate catheter exchange and increase the working
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... New data show the,investigational drug tetrabenazine maintained ... up to 80 weeks in those,patients who ... data suggest that tetrabenazine can be used ... use., "These findings demonstrate the potential benefit ...
... Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical company, ... respected scientific,journal 'Synapse'* on its Phase II NMDA ... a potential treatment for neuropathic,pain. The independent study ... with CNS 5161. , In the study reported ...
Cached Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... nanodot technology, Berkeley Lab researchers have demonstrated the ... used to study the membranes of living cells. ... structures can reveal information critical to whether a ... cancerous, that can,t be obtained through conventional microscopy. ... provide a physical means to both probe and ...
(Date:4/22/2014)... (trade name: NovoEight) has been approved since November 2013 ... with haemophilia A. In an early benefit assessment pursuant ... for Medicinal Products" (AMNOG), the German Institute for Quality ... new active ingredient offers an added benefit over the ... an added benefit of turoctocog alfa is not proven. ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3
... and SANTA CLARA, Calif., Jan. 13 Gulf ... care facilities in,the nation, announced it will be ... ultrasound platforms from Eklin Medical Systems.,GCVS currently uses ... and Communications System) as part of the,facility,s Eklin ...
... respiratory distress, researchers say; company says product is safe ... cold remedy Vicks VapoRub may cause airway inflammation that ... study says. , Doctors at Wake Forest University started ... developed severe respiratory distress after the salve had been ...
... Interventions Incorporated into, First-of-its-Kind Study ... Jan. 13 /PRNewswire/ - MEMOTEXT announced today that ... will conduct a clinical trial on patient adherence ... technology developed by MEMOTEXT. The clinical trial, titled ...
... KENNEBUNK, Maine, Jan. 13 The new year brings ... its steadfast commitment to community programs. This month, the ... brings everyday Americans and local communities together with Tom,s ... care for families in need. Over the past four ...
... new turn. Now you can see the ... Early on Christmas morning, CNN ... "What is Telemedicine?" demonstrating how telemedicine is ... healthcare to patients at six area Walmart ...
... Synergy Connect(TM) links health plan, physicians and ... Fla., Jan. 13 Health Integrated, a ... helping people with chronic illnesses get the ... communities. Health Integrated,s groundbreaking Synergy Connect(TM) service ...
Cached Medicine News:Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 2Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 3Health News:Vicks VapoRub Linked to Infant Breathing Problems 2Health News:Vicks VapoRub Linked to Infant Breathing Problems 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 2Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 4Health News:Tom's of Maine Invites Everyone to Start the New Year by Helping Families in Need 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 3Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 2Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 3
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
... Implants provide the surgeon with ... of the inferior and lateral ... secondary rim repair. The extended ... and extends around the lateral ...
... Round handle. Divides nucleus for phacoemulsification. Nuclear ... any hardness can be pre-chopped with pre-chop ... nuclear fragments is rapid. Risk of rupturing ... ultra sound time and minimal movement of ...
Phaco chopper 1 mm fully cutting edge....
Medicine Products: